TP53 and hepatocellular carcinoma: Notably, TP53 mutations with high VAFs in HCC are frequently linked to impaired p53 signaling, contributing to therapeutic resistance, increased tumor aggressiveness, and defective apoptotic responses (Vokes et al., 2022).